Award Data

N/A

DESCRIPTION (provided by applicant): Rapid and accurate detection and identification of pathogens is crucial for the effective management and treatment of infectious disease. While molecular diagnostic techniques including PCR are a promising approach for rapid and sensitive detection of pathogens, they suffer from a number of technical drawbacks which have slowed their acceptance in the clinic. ...

DESCRIPTION (provided by applicant): In this proposal, we present a novel approach for the identification and immobilization of a BMP mimetic. We plan to use phage display technology to identify peptides that mimic BMP-like signaling of the BMP receptors. These peptides will be linked to a previously identified high-affinity, collagen-binding peptide. The resulting hybrid molecule will allow contr ...

Endosseous metallic implants are common alloplastic devices used in medicine and dentistry. The orthopedic and dental marketplace continues to grow and indications for implants are expanding. There is a perceived need to improve both the successful healing (osseointegration) and the long term outcome of implants by control of interfacial reactivity during healing and remodeling. The growth of know ...

DESCRIPTION (provided by applicant): In this Phase I SBIR project Alderon Biosciences Inc. (ABI) proposes to demonstrate the feasibility of using electrochemical reverse transcriptase (eRT) assays for determinations of HIV viral load in clinical samples. Success will set the stage for Phase II development, FDA approval, and production of commercial kits using this advanced technology. The long-r ...

DESCRIPTION (provided by applicant): The National Institutes of Allergy and Infectious Disease have called for better tools for the detection and diagnosis of emerging and re-emerging infectious diseases. To meet this need, Alderon Biosciences Inc. (ABI) proposes to develop innovative, low-cost tests with sensitivity adequate for determining HCV viral load. Reliable and affordable HCV viral load t ...

DNA microarray technology, in combination with statistical and predictive modeling tools, could be used to evaluate thousands of genes against distinct gene expression patterns induced by chemical/biological agents to provide early identification and speed therapeutic intervention. The overall objective of this Phase II effort is to leverage existing public domain resources and commercial tools t ...

DESCRIPTION (provided by applicant): Founded in 1998, Altea Therapeutics is developing its PassPort(tm) system to deliver proteins and peptides, small-molecule drugs, genes and vaccines from a skin patch, eliminating the need for invasive needle injection. This breakthrough technology, currently undergoing Phase 1 clinical trials for basal insulin delivery, revolutionizes the way in which medicine ...

DESCRIPTION (provided by applicant): Founded in 1998, Altea Therapeutics is developing its PassPort(tm) transdermal drug delivery system to deliver proteins and peptides, small-molecule drugs, genes and vaccines from a skin patch, eliminating the need for invasive needle injection. This breakthrough technology, currently undergoing Phase 1 clinical trials for transdermal delivery of insulin and ...

DESCRIPTION (provided by applicant): Apeliotus Technologies proposes to develop a commercial diagnostic for the early detection of age-related macular degeneration (ARMD). It relies on a functional test of dark adaptation kinetics (the transition from being light-adapted to being dark-adapted) that has been shown in previous work to detect the onset of ARMD at least four years before it is clinic ...